Peptide research profile
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that is used clinically for the treatment of HIV-associated lipodystrophy (abnormal fat distribution in individuals with HIV). It is also being researched for its potential to improve peripheral nerve health and slow the progression of mild cognitive impairment while reducing fat mass.
Dosing literacy
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context—not a protocol or recommendation.
Recorded amount context
Recorded example with no verified study backing; shown for amount literacy only.
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Schedule literacy
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Research best practices
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Research orientation
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
Tesamorelin: An Analogue of GHRH Tesamorelin is an analogue of growth hormone-releasing hormone (GHRH), and it shares similar effects with GHRH and other GHRH analogues like sermorelin, GRF (1-29), and CJC-1295.…
Tesamorelin reduces inflammation, lowers cardiovascular risk, and supports healthy growth hormone levels, particularly in HIV patients. It also shows promise in treating peripheral nerve damage and cognitive impairment.
Evidence map
Available context is organized without assigning unsupported study models or evidence grades.
Tesamorelin: An Analogue of GHRH Tesamorelin is an analogue of growth hormone-releasing hormone (GHRH), and it shares similar effects with GHRH and other GHRH analogues like sermorelin, GRF (1-29), and CJC-1295.…
Tesamorelin reduces inflammation, lowers cardiovascular risk, and supports healthy growth hormone levels, particularly in HIV patients. It also shows promise in treating peripheral nerve damage and cognitive impairment.
Recorded protocol library
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
500 mcg
Sign in for schedule, duration and source context.
2000 mcg
Sign in for schedule, duration and source context.
Technical reference
Source review